Similar articles

• The HIV vaccine pipeline, from preclinical to phase III.

  Schultz AM, Bradac JA. Schultz AM, et al. AIDS. 2001;15 Suppl 5:S147-58. doi: 10.1097/00002030-200100005-00018. AIDS. 2001. PMID: 11816163 Review. No abstract available.
• [Development of a vaccine against HIV: is this aim accomplishable?].

  Wagner R, Asbach B. Wagner R, et al. MMW Fortschr Med. 2013 Jun 13;155 Suppl 1:36-9. MMW Fortschr Med. 2013. PMID: 23961653 German. No abstract available.
• Novel adjuvants and delivery systems for HIV vaccines.

  O'Hagan DT, Lavelle E. O'Hagan DT, et al. AIDS. 2002;16 Suppl 4:S115-24. AIDS. 2002. PMID: 12699008 Review. No abstract available.
• HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.

  Liu Q, Li Y, Luo Z, Yang G, Liu Y, Liu Y, Sun M, Dai J, Li Q, Qin C, Shao Y. Liu Q, et al. AIDS. 2015 Mar 27;29(6):649-58. doi: 10.1097/QAD.0000000000000595. AIDS. 2015. PMID: 25849828
• Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.

  Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, Martin JE, Rucker S, Andrews CA, Gomez PL, Mascola JR, Nabel GJ, Graham BS; VRC 007 Study Team. Catanzaro AT, et al. Vaccine. 2007 May 16;25(20):4085-92. doi: 10.1016/j.vaccine.2007.02.050. Epub 2007 Mar 7. Vaccine. 2007. PMID: 17391815 Clinical Trial.